Drug Profile
Research programme: local enzyme pro-drug chemotherapeutics - DevaCell
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator DevaCell
- Class Enzymes
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Solid-tumours(Neoadjuvant therapy) in USA (Intratumoural)
- 11 Aug 2016 Early research in Solid tumours (Neoadjuvant therapy) in USA (Intratumoural)